Galvus revenue trends
In 3Q17, Novartis’s (NVS) Galvus reported revenues of ~$310 million, which was ~1% higher YoY (year-over-year). Galvus (vildagliptin) is indicated for the treatment of adult individuals with type-2 diabetes mellitus.
Diovan, Co-Diovan revenue trends
In 3Q17, Diovan and Co-Diovan generated revenues of ~$231 million, which was ~11% lower YoY and 4% lower QoQ (quarter-over-quarter).
Diovan (valsartan) is used for the treatment of hypertension and heart failure and acts by lowering blood pressure in individuals with hypertension. Diovan is also used for diminishing cardiovascular mortality in clinically stable patients with left ventricular failure post-myocardial infarction.
Exforge revenue trends
In 3Q17, Exforge generated revenues of $244 million, which was ~5% higher YoY and 2% higher QoQ. Despite generic competition in the US and Japan, Exforge witnessed revenue growth.
Exforge (amlodipine and valsartan) is used for the treatment of hypertension.
Voltaren-Cataflam and the Exelon-Exelon patch
In 3Q17, Voltaren-Cataflam generated revenues of $118 million, which was ~10% lower YoY but 8% higher QoQ. Voltaren (diclofenac) is used for pain management.
In 3Q17, the Exelon-Exelon patch generated revenues of $95 million, which was ~9% lower YoY and 6% lower QoQ. The Exlelon patch (rivastigmine) is used for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
Ritalin-Focalin revenue trends
In 3Q17, Ritalin-Focalin generated revenues of ~$44 million, which was ~29% lower YoY and 28% lower QoQ. Ritalin (methylphenidate) is used for the treatment of attention deficit hyperactivity disorder (or ADHD) or attention deficit disorder (or ADD).
Notably, the Pharmaceutical ETF (PPH) invests ~4.9%, ~5.4%, and ~4.7% of its total portfolio holdings, respectively, in Novartis, AstraZeneca, and Merck.